Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum’s new drug application for ...

ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Highlights,Iterum Therapeutics receives FDA approval for its new drug, ORLYNVAH.,ORLYNVAH targets uncomplicated urinary tract ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

The clinical-stage pharmaceutical company said Friday that the Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract ...

Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for ...

DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and ...

都柏林和芝加哥 - Iterum Therapeutics plc (NASDAQ:ITRM) 今天宣布,美国食品和药物管理局(FDA)已批准其新药申请ORLYNVAH™(sulopenem etzadroxil和probenecid)。该药物适用于治疗成年女性的非复杂性尿路感染(uUTIs),特别是由大肠杆菌、肺炎克雷伯菌或奇异变形杆菌引起的感染。ORLYNVAH™是美国首个获批的口服青霉烯类抗 ...